29th Dec |
Appendix 3B |
29th Dec |
Change of Director's Interest Notice x 4 |
15th Dec |
Appendix 3B |
13th Dec |
Net Tangible Asset Backing |
8th Dec |
Appendix 3B |
8th Dec |
Eagle Begins Shipment of Omni Innovation’s Diabetes Product |
7th Dec |
Meluka Health to Develop Honey Water for Chinese Market |
6th Dec |
Eve Completes 50% Investment in Meluka Health |
1st Dec |
Appendix 3B |
1st Dec |
Change of Director's Interest Notice x 2 |
30th Nov |
Response to ASX Price & Volume Query |
27th Nov |
Change of Director’s Interest Notice |
27th Nov |
NSW Grant for Honey Research Successful |
27th Nov |
Appendix 3B |
23rd Nov |
Appendix 3Y |
22nd Nov |
Medic Honey Produces a Hemp Seed Honey |
22nd Nov |
Results of Annual General Meeting |
22nd Nov |
Prospectus |
22nd Nov |
Appendix 3B |
15th Nov |
Sydney Investor Roadshow Presentation |
14th Nov |
Net Tangible Asset Backing |
13th Nov |
Philip Owens Appointed CEO of Omni Innovation |
9th Nov |
Meluka Honey Branding and Marketing Commences |
6th Nov |
Supply Agreement with Large Producer of Australian Organic Honey |
2nd Nov |
Meluka Health Appoints Leading Bee And Honey Advisor |
31st Oct |
Eagle Commences Production of Omni Innovation’s Pre‐Meal Shake |
24th Oct |
Appendix 4C - Quarterly |
24th Oct |
Notice of Annual General Meeting and Proxy Form |
24th Oct |
Appendix 4G and Corporate Governance Statement |
24th Oct |
Annual Report to Shareholders |
20th Oct |
Annual Report to Shareholders |
20th Oct |
Appendix 4G and Corporate Governance Statement |
20th Oct |
Notice of Annual General Meeting/Proxy Form |
20th Oct |
Appendix 4C - Quarterly |
18th Oct |
Replacement Appendix 3B |
16th Oct |
Initial Director's Interest Notice |
13th Oct |
Appendix 3B |
13th Oct |
Prospectus |
10th Oct |
Net Tangible Asset Backing |
6th Oct |
$1.2M Capital Raising |
2nd Oct |
Update on Capital Raising |
27th Sep |
Suspension from Official Quotation |
25th Sep |
Trading Halt |
22nd Sep |
Omni Innovation Executes Chinese Licence Agreement |
20th Sep |
Net Tangible Asset Backing |
1st Sep |
Appendix 4E and Full Year Statutory Accounts |
28th Aug |
Revised Medical Honey Investment Structure |
16th Aug |
Omni Innovation Enters Chinese Distribution Agreement with Eagle Health |
14th Aug |
Net Tangible Asset Backing |
14th Aug |
Trading Halt |
31st Jul |
Appendix 4C - Quarterly |
14th Jul |
Net Tangible Asset Backing |
5th Jul |
Change of Director's Interest Notice x 3 |
4th Jul |
Prospectus |
4th Jul |
Appendix 3B |
26th Jun |
Results of General Meeting |
26th Jun |
Accelerating Portfolio Progress |
15th Jun |
Net Tangible Asset Backing |
31st May |
Investor Presentation |
30th May |
Southern Cross University Collaboration with Medic Honey |
25th May |
Notice of General Meeting/Proxy Form |
18th May |
Appointment of Leading Medicinal Cannabis Advisor |
12th May |
Net Tangible Asset Backing |
9th May |
Change in Substantial Holding |
9th May |
Change of Director's Interest Notice x 3 |
9th May |
Replacement Appendix 3B |
5th May |
Prospectus |
5th May |
Appendix 3B |
5th May |
EVE Capital Raising Completed |
3rd May |
EVE Capital Raising Oversubscribed |
2nd May |
Reinstatement to Official Quotation |
1st May |
Eve Invests in Pioneering Cannabis Honey & Tea Tree Oil Co |
28th Apr |
Appendix 4C - Quarterly |
21st Apr |
LNK: Change of Perth Address for Shareholder Purposes |
21st Apr |
Update on Capital Raising |
18th Apr |
Update on Capital Raising |
13th Apr |
Net Tangible Asset Backing |
10th Apr |
Update on Capital Raising |
3rd Apr |
Update on Capital Raising |
27th Mar |
Voluntary Suspension |
23rd Mar |
Trading Halt |
23rd Mar |
Omni Innovation - US Manufacturer Appointed |
22nd Mar |
Omni Innovation Completes UK Licence Agreement |
14th Mar |
Net Tangible Asset Backing |
8th Mar |
Omni Innovation US Update |
1st Mar |
Omni Innovation - US Patent Notice of Allowance Received |
28th Feb |
Omni Innovation Update |
28th Feb |
Half Yearly Report and Accounts |
14th Feb |
Results of Meeting |
13th Feb |
Net Tangible Asset Backing |
30th Jan |
Appendix 4C - Quarterly |
25th Jan |
Sales Results Exceed Expectations for Faulding GlucoControl |
17th Jan |
Change of Director's Interest Notice |
12th Jan |
Notice of General Meeting/Proxy Form |
11th Jan |
Net Tangible Asset Backing |
11th Jan |
Change in Substantial Holding |